- Home
- CNTX vs NCSM Comparison
CNTX vs NCSM Comparison
Compare CNTX & NCSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- NCSM
- Stock Information
- Founded
- CNTX 2015
- NCSM 2006
- Country
- CNTX United States
- NCSM United States
- Employees
- CNTX N/A
- NCSM N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- NCSM Oilfield Services/Equipment
- Sector
- CNTX Health Care
- NCSM Energy
- Exchange
- CNTX Nasdaq
- NCSM Nasdaq
- Market Cap
- CNTX 60.7M
- NCSM 61.1M
- IPO Year
- CNTX 2021
- NCSM 2017
- Fundamental
- Price
- CNTX $0.84
- NCSM $28.64
- Analyst Decision
- CNTX Strong Buy
- NCSM
- Analyst Count
- CNTX 5
- NCSM 0
- Target Price
- CNTX $6.50
- NCSM N/A
- AVG Volume (30 Days)
- CNTX 257.9K
- NCSM 13.6K
- Earning Date
- CNTX 05-07-2025
- NCSM 04-30-2025
- Dividend Yield
- CNTX N/A
- NCSM N/A
- EPS Growth
- CNTX N/A
- NCSM N/A
- EPS
- CNTX N/A
- NCSM 2.55
- Revenue
- CNTX N/A
- NCSM $162,557,000.00
- Revenue This Year
- CNTX N/A
- NCSM $7.03
- Revenue Next Year
- CNTX N/A
- NCSM $5.82
- P/E Ratio
- CNTX N/A
- NCSM $11.23
- Revenue Growth
- CNTX N/A
- NCSM 14.10
- 52 Week Low
- CNTX $0.55
- NCSM $15.90
- 52 Week High
- CNTX $2.75
- NCSM $38.95
- Technical
- Relative Strength Index (RSI)
- CNTX 56.99
- NCSM 46.67
- Support Level
- CNTX $0.80
- NCSM $25.09
- Resistance Level
- CNTX $0.89
- NCSM $28.95
- Average True Range (ATR)
- CNTX 0.11
- NCSM 2.72
- MACD
- CNTX 0.03
- NCSM -0.66
- Stochastic Oscillator
- CNTX 73.80
- NCSM 25.62
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.